In the German Breast Cancer Study Group (GBSG) multicenter trial "Breast preservation in small breast cancer" 1119 patients were accrued over a period of six years. The study was originally designed as a randomized trial which had to be changed into a prospective observation study. A high therapeutic standard was guaranteed by quality control. The univariate analysis of prognostic variables was the first step to a valid treatment comparison. Those factors determined as being significant were combined with the treatment effects in a multivariate analysis. The published results were obtained after a median observation time of four years.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Reconfiguring Priorities: Breastfeeding Decision-making Among Young Breast Cancer Survivors.
Cancer Nurs
January 2025
Author Affiliations: Department Research, Hospital Germans Trias i Pujol, Universitat Autonòma de Barcelona; and NURECARE Research Group, Institut d'Investigació i Hospital Germans Trias i Pujol (IGTP), Ctra de Can Ruti, Camí de les Escoles (Dr Huertas-Zurriaga); Department Research, Institut Català Oncologia-Hospital Germans Trias i Pujol; Universitat Autonòma de Barcelona; GRIN Group, IDIBELL, Institute of Biomedical Research; and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Cabrera-Jaime); Tecnocampus University and NURECARE Research Group, IGTP, Ctra de Can Ruti, Camí de les Escoles (Dr Navarri); Oncology Department, Hereditarian Cancer Program, Institut Català Oncologia-Hospital Germans Trias i Pujol, B-ARGO (Badalona Applied Research Group in Oncology), IGTP (Health Research Institute Germans Trias i Pujol), Universitat Autònoma de Barcelona (Dr Teruel-Garcia); and Nursing Research Group in Vulnerability and Health (GRIVIS); and Nursing Department, Faculty of Medicine, Universitat Autònoma de Barcelona (Dr Leyva-Moral), Badalona, Spain.
Article Synopsis
- Breast cancer survivors experience unique challenges when making decisions about breastfeeding, with limited research on their experiences.
- The study revealed that young women often prioritize other aspects of their cancer journey over breastfeeding, influenced by factors like the effects of treatment and support gaps from healthcare providers.
- To improve care, it's crucial for healthcare professionals to address breastfeeding in oncological discussions, involve lactation consultants familiar with oncology, and create peer support programs that empower survivors.
Ezrin Polarization as a Diagnostic Marker for Circulating Tumor Cells in Hepatocellular Carcinoma.
Cells
December 2024
Department of General, Visceral and Transplant Surgery, University Hospital Muenster, University of Muenster, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related death worldwide, with no precise method for early detection. Circulating tumor cells (CTCs) expressing the dynamic polarity of the cytoskeletal membrane protein, ezrin, have been proposed to play a crucial role in tumor progression and metastasis. This study investigated the diagnostic and prognostic potential of polarized circulating tumor cells (p-CTCs) in HCC patients.
View Article and Find Full Text PDFImplant-based reconstruction and adjuvant radiotherapy in breast cancer patients-current status and DEGRO recommendations.
Strahlenther Onkol
January 2025
Department of Radiation Oncology, University Hospital Düsseldorf, Düsseldorf, Germany.
Purpose: The aim of this review is to give an overview of the results of prospective and retrospective studies using allogenic reconstruction and postmastectomy radiotherapy (PMRT) in breast cancer and to make recommendations regarding this interdisciplinary approach.
Materials And Methods: A PubMed search was conducted to extract relevant articles from 2000 to 2024. The search was performed using the following terms: (breast cancer) AND (reconstruction OR implant OR expander) AND (radiotherapy OR radiation).
RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
Clin Cancer Res
December 2024
Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Purpose: The randomized GeparOla trial reported comparable pathological complete response (pCR) rates with neoadjuvant containing olaparib vs. carboplatin treatment. Here, we evaluate the association between functional homologous repair deficiency (HRD) by RAD51 foci and pCR, and the potential of improving patient selection by combining RAD51 and stromal tumor infiltrating lymphocytes (sTILs).
View Article and Find Full Text PDFPretreatment Fatigue in Breast Cancer Patients: Comparison With Healthy Controls and Associations With Biopsychosocial Variables.
Cancer Med
January 2025
Division of Physical Activity, Prevention and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Objective: Cancer-related fatigue is one of the most common burdens of cancer patients. To date, most studies focused on fatigue during or after treatment. However, investigation of pretreatment fatigue is crucial to identify causal or risk factors other than cancer therapy and to enable timely fatigue management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!